

**HHCS Cryopreserved Human Hepatocytes for Suspension Assays**  
**Cell Specification – Certificate of Analysis (CoA)**

Lot HH130614-1

Batch Release: Sept 28, 2020

Updated: March 14, 2023

Species: Human		Gender: male		Age: 53 years				
		Size: 191 cm		Weight: 90 kg				
		Non-Smoker						
Serology: HAV, HBV, HCV, HIV 1/2: negative		Diagnosis: liver metastasis in left lobe						
Medical History: Chemotherapy (Folfox 4 protocol) until 03/2012		Therapy: liver resection						
Medication: Fragmin P forte								
<b>Cryopreservation:</b>		<b>Thawing:</b> n=5						
Date:	June 14, 2013	Post-thaw viability: 80.8 ± 7.4 %						
Amount per vial:	15.0 x 10 <sup>6</sup> cells	Post-thaw yield per vial: 7.4 ± 0.4 x 10 <sup>6</sup> cells						
		Recovery: 49 ± 3 %						
Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10 <sup>6</sup> cells in 0.5 ml HPM-Cryo): n=2								
Time (h)	0	0.5	1	1.5	2	3	4	5
Viability (%)	88.4	71.7	74.4	72.5	72.0	68.56	71.4	60.0
Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT’s manual for thawing, plating and culture of primary cryopreserved hepatocytes.								
<b>Store at -150 °C or in the vapour phase of LN<sub>2</sub></b>								
This product should be considered as potential biohazard. Only intended for <i>in vitro</i> use.								
Issued by: A. Alkufairi			Verified by: A. Ullrich					